Pyxis Oncology
PYXS • NASDAQ
Pyxis Oncology is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Thomas Civik, with a market cap of $82.3M.
CEOThomas Civik
Next Earnings
Upcoming earnings announcement for Pyxis Oncology
Date
Thursday, May 14, 2026 (in a month)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.36
Earnings History
Past 12 earnings reports for Pyxis Oncology
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 23, 2026 | Q4 2025 | -$0.29Est: -$0.34 | +14.7% | $11.0M | — |  10-K |
| Nov 3, 2025 | Q3 2025 | -$0.35Est: -$0.35 | 0.0% | - | — | 10-Q |
| Aug 14, 2025 | Q2 2025 | -$0.30Est: -$0.36 | +16.7% | $2.8M | — | 10-Q |
| May 15, 2025 | Q1 2025 | -$0.35Est: -$0.30 | -16.7% | - | — | 10-Q |
| Mar 18, 2025 | Q4 2024 | -$0.59Est: -$0.29 | -103.4% | - | — | 10-K |
| Nov 12, 2024 | Q3 2024 | -$0.35Est: -$0.30 | -16.7% | - | — | 10-Q |
| Aug 14, 2024 | Q2 2024 | -$0.29Est: -$0.28 | -3.6% | - | — | 10-Q |
| May 14, 2024 | Q1 2024 | -$0.06Est: -$0.22 | +72.7% | $16.1MEst: $4.1M | +291.9% | 10-Q |
| Mar 21, 2024 | Q4 2023 | -$0.33Est: -$0.47 | +29.8% | -Est: $170.0K | -100.0% | 10-K |
| Nov 7, 2023 | Q3 2023 | -$0.56Est: -$0.51 | -9.8% | - | — | — |
| Aug 11, 2023 | Q2 2023 | -$0.41Est: -$0.66 | +37.9% | - | — | 10-Q |
| May 11, 2023 | Q1 2023 | -$0.54Est: -$0.90 | +40.0% | - | — | — |